2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6870
Lung Neoplasms
5102
Small Cell Lung Carcinoma
1166
Breast Neoplasms
855
Neoplasms
762
Colorectal Neoplasms
668
Melanoma
566
Ovarian Neoplasms
506
Neoplasm Metastasis
480
Pancreatic Neoplasms
472
Adenocarcinoma of Lung
397
Stomach Neoplasms
396
Prostatic Neoplasms
370
Head and Neck Neoplasms
367
Carcinoma, Renal Cell
350
Esophageal Neoplasms
337
Squamous Cell Carcinoma of Head and Neck
325
Mesothelioma, Malignant
324
Colonic Neoplasms
293
Mesothelioma
289
Urinary Bladder Neoplasms
262
Brain Neoplasms
254
Uterine Cervical Neoplasms
243
Triple Negative Breast Neoplasms
222
Sarcoma
197
Endometrial Neoplasms
196
Carcinoma, Hepatocellular
186
NSCLC
167
Pleural Effusion, Malignant
160
Kidney Neoplasms
160
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA